# Genrix (Shanghai) Biopharmaceutical trials: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genrix (Shanghai) Biopharmaceutical Co., Ltd.: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genrix-shanghai-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07930039 | A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo. | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Vitiligo | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930039) |
| June 15, 2026 | NCT07647237 | A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Vitiligo | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647237) |
| June 15, 2026 | NCT07647224 | A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China. | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Multiple Dose, Healthy Adult Participants | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647224) |
| March 5, 2026 | NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple... | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Multiple Myeloma | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07452198) |
| January 16, 2026 | NCT07348055 | A Study of GR1803 in Systemic Lupus Erythematosus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Systemic Lupus Erthematosus, Auto Immune Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348055) |
| September 30, 2025 | NCT07199270 | A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Health Adult Subjects | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199270) |
| September 30, 2025 | NCT07199257 | A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Allergic Rhinitis, Seasonal | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199257) |
| September 24, 2025 | NCT07190716 | A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers. | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Single Ascending Dose, Healthy Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190716) |
| September 4, 2025 | NCT07154342 | A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Allergic Rhinitis, Seasonal | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154342) |
| August 5, 2025 | NCT07102706 | Phase I Trial of GR1803 Injection in Patients With RRMM | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Completed | Multiple Myeloma (MM) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07102706) |
| July 29, 2025 | NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090954) |
| April 30, 2025 | NCT06952075 | GR1803 Injection in Patients With RRMM | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Multiple Myleoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952075) |
| October 15, 2024 | NCT06642961 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in... | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Asthma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06642961) |
| October 10, 2024 | NCT06635798 | A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Unknown | Tetanus | 582 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06635798) |
| August 22, 2024 | NCT06566547 | GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Multiple Myeloma | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06566547) |
| July 23, 2024 | NCT06516302 | A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Chronic Rhinosinusitis With Nasal Polyps | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06516302) |
| March 18, 2024 | NCT06315426 | A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Allergic Rhinitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315426) |
| March 15, 2024 | NCT06313697 | A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Respiratory Syncytial Virus Infections | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06313697) |
| March 8, 2024 | NCT06302374 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Completed | Tetanus | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06302374) |
| January 22, 2024 | NCT06216392 | Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Unknown | Atopic Dermatitis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06216392) |
| December 18, 2023 | NCT06175143 | A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Atopic Dermatitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06175143) |
| August 29, 2023 | NCT06015243 | The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Chronic Rhinosinusitis With Nasal Polyps | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06015243) |
| August 29, 2023 | NCT06015230 | Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Active not recruiting | Lupus Erythematosus, Systemic | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06015230) |
| July 20, 2023 | NCT05954611 | The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Asthma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05954611) |
| May 31, 2023 | NCT05881785 | Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Axial Spondyloarthritis | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05881785) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 6 |
| Phase 2 | 8 |
| Phase 3 | 8 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 7 |
| Completed | 7 |
| Not yet recruiting | 6 |
| Recruiting | 5 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 4 |
| Lupus Erythematosus, Systemic | 2 |
| Autoimmune Diseases | 2 |
| Rhinitis, Allergic, Seasonal | 2 |
| Asthma | 2 |
| Axial Spondyloarthritis | 2 |
| Tetanus | 2 |
| Vitiligo | 2 |
| Dermatitis, Atopic | 2 |
| Rhinitis, Allergic | 1 |
| Respiratory Syncytial Virus Infections | 1 |
| Respiratory Tract Infections | 1 |
| Rabies | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Brazilian restaurants in the United States](https://specstream.ai/data/businesses/brazilian-restaurants/united-states)
- [Agricultural cooperatives in the United States](https://specstream.ai/data/businesses/agricultural-cooperatives/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Product design firms in the United States](https://specstream.ai/data/businesses/product-design-firms/united-states)
- [Middle schools in the United States](https://specstream.ai/data/businesses/middle-schools/united-states)
